Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib
oleh: Konstantinos Anargyrou, Evangelos Terpos, Theodoros P. Vassilakopoulos, Anastasia Pouli, Sotirios Sachanas, Tatiana Tzenou, Stavroula Masouridis, Dimitrios Christoulas, Maria K. Angelopoulou, Evangelia M. Dimitriadou, Christina Kalpadakis, Konstantinos Tsionos, Panayiotis Panayiotidis, Meletios A. Dimopoulos, Gerassimos A. Pangalis, Marie-Christine Kyrtsonis
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2008-03-01 |
Deskripsi
Neoangiogenesis is involved in the pathophysiology of multiple myeloma and angiopoietins possibly contribute to myeloma-induced neovascularization. Bortezomib’s antineoplastic potential includes an anti-angiogenic effect. We determined serum levels of angiopoietin-1 and angiopoietin-2 with ELISA pre- and post-bortezomib administration in 35 patients with relapsed/refractory multiple myeloma. Pre-bortezomib, serum angiopoietin-1 levels did not differ in patients and in healthy individuals, while serum angiopoietin-2 levels were elevated. Corresponding serum angiopoietin-1/angiopoietin-2 ratio was reduced in patients compared with controls. After treatment, serum angiopoietin-1 levels increased, while serum angiopoietin-2 levels decreased, therefore the angiopoietin-1/angiopoietin-2 ratio increased and normalized. This increase was significant in patients who responded to treatment. In conclusion, angiopoietin-1/angiopoietin-2 ratio normalization reflected response to bortezomib.